Microaneurysm turnover IDs macular edema development

January 8, 2013
Microaneurysm turnover IDs macular edema development
Microaneurysm turnover independently predicts the development of clinically significant macular edema in patients with non-proliferative diabetic retinopathy, according to a study published online Nov. 30 in Diabetes Care.

(HealthDay)—Microaneurysm (MA) turnover independently predicts the development of clinically significant macular edema (CSME) in patients with non-proliferative diabetic retinopathy (NPDR), according to a study published online Nov. 30 in Diabetes Care.

Maria Luisa Ribeiro, M.D., from the University of Coimbra in Portugal, and colleagues conducted a prospective observational study involving 410 patients (one eye per patient) with and NPDR and no prior laser treatment. Participants were followed for two years or until development of CSME. MA turnover was assessed using automated analysis of fundus photographs (RetmarkerDR). Ophthalmologic examinations were performed at baseline, six months, and at the last study visit (24 months or before ).

The researchers found that, of the 348 eyes/patients who were followed until the last visit, 26 developed CSME. CSME development was independently predicted by hemoglobin A1c levels at baseline and MA turnover (the sum of the MA formation and disappearance rates) computed during the first six months of follow-up. In the 26 eyes/patients who developed CSME, MA turnover was 11.2 ± 11.2, compared with 5.0 ± 5.2 in the remaining 322 patients (P < 0.001). There was a correlation between higher MA turnover values and earlier development of CSME. For CSME development, the positive predictive value of MA turnover was 20 percent and the negative predictive value was 96 percent.

"MA turnover calculated with the RetmarkerDR predicts development of CSME in eyes with NPDR," the authors write. "Low MA turnover values identify well the eyes that are less likely to develop CSME in a two-year period."

The authors disclosed financial ties to the Association for Innovation and Biomedical Research on Light and Image. One author disclosed to the pharmaceutical industry.

Explore further: Study reports two-year outcomes of diabetic macular edema treatment

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study examines effects of Ibudilast and metamphetamines

April 25, 2012

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, ...

Long-term ranibizumab beneficial for macular edema

October 11, 2012

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according ...

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.